指南与共识神经免疫

儿童多发性硬化疾病修正疗法的临床试验:IPMSSG的机遇、挑战与建议

Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG.
指南 / 共识 · Neurology · 2019-05-01

国际儿童多发性硬化研究组召开专家会议,基于儿童与成人MS生物学过程共享及儿童期高复发频率,讨论儿童MS疾病修正疗法的临床试验设计。会议指出每项成人新药均开展儿童III期试验不可行,需重新考虑研究设计与实施,以平衡疗效与安全性证据需求。

要点

  • 儿童与成人MS生物学过程高度共享,成人有效药物具儿童应用生物学依据
  • 儿童MS试验面临重大招募挑战,每项成人新药均做儿童III期试验不可行
  • 需根据所需信息重新考虑研究设计,明确疗效或安全性为主要目标

核心结论

  • 主要目标是确保儿童和青少年MS患者获得高质量循证治疗,增进对药物安全性的理解并消除监管或保险限制。

研究设计与样本

  • 国际儿童多发性硬化研究组召开专家会议,审查儿童期发病MS的理解进展及该人群临床试验的出现。

主要发现

  • 近年有令人信服的证据表明MS涉及的生物学过程在年龄跨度上基本共享。
  • 对成人MS有效的治疗因儿童MS起病为复发缓解型且复发频率高而具有生物学依据。
  • 近期完成和正在进行的儿童MS试验面临重大招募挑战。
  • 每项新获批成人MS疗法在儿童MS人群中开展III期试验不可行。

临床怎么用

  • 需根据所需信息重新考虑研究设计与实施,明确研究是为疗效还是以安全性为主要目标。
  • 在儿童MS试验中需考虑伦理问题,包括因疾病高度活动而使用安慰剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The impetus for this consensus discussion was to recommend clinical trial designs that can deliver high-quality data for effective therapies for pediatric patients, in a reasonable timeframe, with a key focus on short- and long-term safety. METHODS: The International Pediatric Multiple Sclerosis Study Group convened a meeting of experts to review the advances in the understanding of pediatric-onset multiple sclerosis (MS) and the advent of clinical trials for this population. RESULTS: In the last few years, convincing evidence has emerged that the biological processes involved in MS are largely shared across the age span. As such, treatments proven efficacious for the care of adults with MS have a biological rationale for use in pediatric MS given the relapsing-remitting course at onset and high relapse frequency. There are also ethical considerations on conducting clinical trials in this age group including the use of placebo owing to highly active disease. It is imperative to reconsider study design and implementation based on what information is needed. Are studies needed for efficacy or should safety be the primary goal? Further, there have been major recruitment challenges in recently completed and ongoing pediatric MS trials. Phase 3 trials for every newly approved therapy for adult MS in the pediatric MS population are simply not feasible. CONCLUSIONS: A primary goal is to ensure high-quality evidence-based treatment for children and adolescents with MS, which will improve our understanding of the safety of these agents and remove regulatory or insurance-based limitations in access to treatment.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Waubant E, Banwell B, Wassmer E, et al. Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG. Neurology. 2019. PMID: 31043474. doi:10.1212/WNL.0000000000007572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。